Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 799 results for "Ibrutinib"

Imbruvica receives European approval for two forms of blood ca...

Janssen-Cilag International announced that the European Commission has approved Imbruvica (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by ... PharmaBiz, 1 day ago
Janssen's Imbruvica Approved by the European Commission American Journal of Managed Care, 4 days ago

18 images for Ibrutinib

OncLive, 1 week ago
British Journal of Haematology, 2 weeks ago
SearchBug, 2 months ago
Drug Discovery and Development, 2 months ago
OncLive, 2 months ago, 2 months ago
Ecancer Medicalscience, 2 months ago
Scottrade, 2 months ago, 4 months ago
MedIndia, 4 months ago

IMBRUVICA (ibrutinib) ya está aprobado en Europa para el tratamiento de dos cánceres sanguíneos

SCHAFFHAUSEN, Suiza, 20 de octubre de 2014 /PRNewswire/ --Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC ), ha anunciado hoy que la Comisión Europea (CE) ha concedido una autorización de marketing para IMBRUVICA ...
 PR Newswire1 day ago La Comisión Europea aprueba IMBRUVICA para dos cánceres sanguíneos  PR Newswire4 days ago
Pharmaceutical Business Review

Janssen Research & Development Release: IMBRUVICA?? (ibrutinib) Supplemental New Drug Application Submitted To The U.S. FDA For Waldenstrom's Macroglobulinemia

RARITAN, N.J. , Oct. 20, 2014 /PRNewswire/ -- Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA ® (ibrutinib) to the U.S. Food and Drug Administration (FDA) by ...
 BioSpace1 day ago IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia  Stock Nod1 day ago Pharmacyclics' Imbruvica gets European approval to treat two blood cancers  Pharmaceutical Business Review1 day ago EC clears Imbruvica  Seeking Alpha4 days ago

Evolution of ibrutinib resistance [Evolution]

A. Burger c , and Dominik Wodarz a , b a Department of Mathematics and b Department of Ecology and Evolutionary Biology, University of California, Irvine , CA 92697; and c Department of Leukemia, MD Anderson Cancer Center , Houston, TX 77230 ...
 PNAS1 month ago

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary ...
 American Journal of Managed Care1 week ago Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration  Technology Networks5 days ago BMS, Pharmacyclics and Janssen collaborate on cancer  Pharmafocus1 week ago BMS, Pharmacyclics, Janssen Enter OPDIVO Clinical pact  Contract Pharma1 week ago

Ibrutinib ameliorates chronic graft-versus-host disease in mice

Ratings require JavaScript to be enabled. Hematopoietic stem cells (HSCs) can differentiate into all types of blood cells, including red blood cells and immune cells. While HSC transplantation can be life saving for patients with ...
 Medical News Today2 weeks ago B and T cell-targeting drug ameliorates chronic graft-versus-host disease in mice  EurekAlert!2 weeks ago

VIDEO: Are chemo-free regimens possible for CLL?

MILAN The Food and Drug Administration has given full approval for ibrutinib for patients with chronic lymphocytic leukemia who have received at least one prior therapy and for those who
 Oncology Report3 weeks ago Combination of ibrutinib, rituximab induced responses in high-risk CLL  Orthopedics Today1 month ago RESONATE STUDY: CLL/SLL Survival Improved with Ibrutinib  CancerWatch2 months ago End of Rituximab Maintenance for Low-Tumor Burden Follicular Lymphoma  Journal of Clinical Oncology2 weeks ago

MCL: Study Identifies Rational Drug Combinations That May Overcome Resistance to Ibrutinib

Oncology Times: doi: 10.1097/01.COT.0000454180.31698.23 News SELINA CHEN-KIANG, PHD Image Tools Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphoma (MCLs) that do not respond to ...
 Oncology Times3 weeks ago John Byrd Joins OT as Clinical Advisory Editor  Oncology Times3 weeks ago John Byrd Joins Oncology Times as Clinical Advisory Editor  Oncology Times1 month ago

Study identifies potential drug combination for mantle cell lymphoma and chronic lymphocytic leukaemia

Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), according to preclinical ...
 Ecancer Medicalscience4 weeks ago

Genetic mutation linked to acquired ibrutinib resistance in MCL

A relapse-specific BTK genetic mutation identified in patients with mantle cell lymphoma may serve as a target to overcome both primary and acquired ibrutinib resistance, according to results of a longitudinal study. Prior studies have found ...
 Orthopedics Today2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less